Processing

Please wait...

Settings

Settings

Goto Application

1. WO2008024725 - AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE

Publication Number WO/2008/024725
Publication Date 28.02.2008
International Application No. PCT/US2007/076344
International Filing Date 20.08.2007
IPC
C07D 491/048 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
044with only one oxygen atom as ring hetero atom in the oxygen-containing ring
048the oxygen-containing ring being five-membered
A61K 31/4355 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4355the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/5025 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
5025ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 29/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
CPC
A61P 1/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
18for pancreatic disorders, e.g. pancreatic enzymes
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
A61P 19/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
Applicants
  • GENENTECH, INC. [US]/[US] (AllExceptUS)
  • PRICE, Stephen [GB]/[GB] (UsOnly)
  • WILLIAMS, Karen [GB]/[GB] (UsOnly)
  • SAVY, Pascal Pierre [FR]/[GB] (UsOnly)
  • DYKE, Hazel Joan [GB]/[GB] (UsOnly)
  • MONTANA, John Gary [GB]/[GB] (UsOnly)
  • STANLEY, Mark S. [US]/[US] (UsOnly)
  • BAO, Liang [CN]/[US] (UsOnly)
Inventors
  • PRICE, Stephen
  • WILLIAMS, Karen
  • SAVY, Pascal Pierre
  • DYKE, Hazel Joan
  • MONTANA, John Gary
  • STANLEY, Mark S.
  • BAO, Liang
Agents
  • WANG, Min
Priority Data
60/839,16121.08.2006US
60/871,59122.12.2006US
60/917,62311.05.2007US
60/944,74118.06.2007US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE
(FR) COMPOSÉS AZA-BENZOFURANYLE ET LEURS PROCÉDÉS D'UTILISATION
Abstract
(EN)
The invention relates to azabenzofuranyl compounds of Formula (I) with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
(FR)
L'invention concerne des composés aza-benzofuranyle de formule (I) présentant une activité anti-cancéreuse et/ou anti-inflammatoire, et en particulier des composés aza-benzofuranyle inhibant l'activité de la MEK-kinase. L'invention concerne des compositions et des procédés servant à inhiber une croissance cellulaire anormale ou à traiter un trouble hyperprolifératif, ou à traiter une maladie inflammatoire chez un mammifère. L'invention concerne également des procédés d'utilisation des composés de l'invention visant à diagnostiquer ou à traiter des cellules de mammifères in vitro, in situ, et in vivo pour des troubles pathologiques associés.
Latest bibliographic data on file with the International Bureau